<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 21: Drug Interactions: Pharmacokinetic Parameters for Atazanavir in the Presence of Coadministered Drugs<sup>a</sup>
</caption>
<col width="19%"></col>
<col width="18%"></col>
<col width="25%"></col>
<col width="13%"></col>
<col width="13%"></col>
<col width="13%"></col>
<thead>
<tr>
<th align="center" rowspan="2" stylecode="Botrule Toprule " valign="top">
<content stylecode="bold">Coadministered Drug</content>
</th>
<th align="center" rowspan="2" stylecode="Botrule Toprule " valign="top">
<content stylecode="bold">Coadministered Drug</content>
<br/>
<content stylecode="bold">Dose/Schedule</content>
</th>
<th align="center" rowspan="2" stylecode="Botrule Toprule " valign="top">
<content stylecode="bold">REYATAZ</content>
<br/>
<content stylecode="bold">Dose/Schedule</content>
</th>
<th align="center" colspan="3" stylecode="Toprule " valign="bottom">
<content stylecode="bold">Ratio (90% Confidence Interval) of Atazanavir Pharmacokinetic Parameters with/without Coadministered Drug;</content>
<br/>
<content stylecode="bold">No Effect = 1.00</content>
</th>
</tr>
<tr>
<th align="center" stylecode="Botrule " valign="bottom">
<content stylecode="bold">C<sub>max</sub>
</content>
</th>
<th align="center" stylecode="Botrule " valign="bottom">
<content stylecode="bold">AUC</content>
</th>
<th align="center" stylecode="Botrule " valign="bottom">
<content stylecode="bold">C<sub>min</sub>
</content>
</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="6" stylecode="Botrule" valign="top">
<sup>a</sup> Data provided are under fed conditions unless otherwise noted.<br/>
<sup>b</sup> All drugs were given under fasted conditions.<br/>
<sup>c</sup> 400 mg ddI EC and REYATAZ were administered together with food on Days 8 and 19.<br/>
<sup>d</sup> REYATAZ 300 mg plus ritonavir 100 mg once daily coadministered with famotidine 40 mg twice daily resulted in atazanavir geometric mean C<sub>max</sub> that was similar and AUC and C<sub>min</sub> values that were 1.79- and 4.46-fold higher relative to REYATAZ 400 mg once daily alone.<br/>
<sup>e</sup> Similar results were noted when famotidine 20 mg BID was administered 2 hours after and 10 hours before atazanavir 300 mg and ritonavir 100 mg plus tenofovir 300 mg.<br/>
<sup>f</sup> Atazanavir/ritonavir/tenofovir was administered after a light meal.<br/>
<sup>g</sup> Study was conducted in HIV-infected individuals.<br/>
<sup>h</sup> Compared with atazanavir 400 mg historical data without nevirapine (n=13), the ratio of geometric means (90% confidence intervals) for C<sub>max</sub>, AUC, and C<sub>min</sub> were 1.42 (0.98, 2.05), 1.64 (1.11, 2.42), and 1.25 (0.66, 2.36), respectively, for atazanavir/ritonavir 300/100 mg; and 2.02 (1.42, 2.87), 2.28 (1.54, 3.38), and 1.80 (0.94, 3.45), respectively, for atazanavir/ritonavir 400/100 mg.<br/>
<sup>i</sup> Parallel group design; n=23 for atazanavir/ritonavir plus nevirapine, n=22 for atazanavir 300 mg/ritonavir 100 mg without nevirapine. Subjects were treated with nevirapine prior to study entry.<br/>
<sup>j</sup> Omeprazole 40 mg was administered on an empty stomach 2 hours before REYATAZ.<br/>
<sup>k</sup> Omeprazole 20 mg was administered 30 minutes prior to a light meal in the morning and REYATAZ 300 mg plus ritonavir 100 mg in the evening after a light meal, separated by 12 hours from omeprazole.<br/>
<sup>l</sup> REYATAZ 300 mg plus ritonavir 100 mg once daily separated by 12 hours from omeprazole 20 mg daily resulted in increases in atazanavir geometric mean AUC (10%) and C<sub>min</sub> (2.4-fold), with a decrease in C<sub>max</sub> (29%) relative to REYATAZ 400 mg once daily in the absence of omeprazole (study days 1−6).<br/>
<sup>m</sup> Omeprazole 20 mg was given 30 minutes prior to a light meal in the morning and REYATAZ 400 mg plus ritonavir 100 mg once daily after a light meal, 1 hour after omeprazole. Effects on atazanavir concentrations were similar when REYATAZ 400 mg plus ritonavir 100 mg was separated from omeprazole 20 mg by 12 hours.<br/>
<sup>n</sup> REYATAZ 400 mg plus ritonavir 100 mg once daily administered with omeprazole 20 mg once daily resulted in increases in atazanavir geometric mean AUC (32%) and C<sub>min</sub> (3.3-fold), with a decrease in C<sub>max</sub> (26%) relative to REYATAZ 400 mg once daily in the absence of omeprazole (study days 1−6).<br/>
<sup>o</sup> Compared with atazanavir 400 mg QD historical data, administration of atazanavir/ritonavir 300/100 mg QD increased the atazanavir geometric mean values of C<sub>max</sub>, AUC, and C<sub>min</sub> by 18%, 103%, and 671%, respectively.<br/>
<sup>p</sup> Note that similar results were observed in studies where administration of tenofovir and REYATAZ was separated by 12 hours.<br/>
<sup>q</sup> Ratio of atazanavir plus ritonavir plus tenofovir to atazanavir plus ritonavir. Atazanavir 300 mg plus ritonavir 100 mg results in higher atazanavir exposure than atazanavir 400 mg (see footnote o). The geometric mean values of atazanavir pharmacokinetic parameters when coadministered with ritonavir and tenofovir were: C<sub>max</sub> = 3190 ng/mL, AUC = 34459 ng•h/mL, and C<sub>min</sub> = 491 ng/mL. Study was conducted in HIV-infected individuals.<br/>NA = not available.</td>
</tr>
</tfoot>
<tbody>
<tr>
<td stylecode="Toprule ">
<paragraph>atenolol</paragraph>
</td>
<td align="center" stylecode="Toprule ">
<paragraph>50 mg QD, d 7−11 (n=19) and d 19−23</paragraph>
</td>
<td align="center" stylecode="Toprule ">
<paragraph>400 mg QD, d 1−11<br/>(n=19)</paragraph>
</td>
<td align="center" stylecode="Toprule ">
<paragraph>1.00<br/>(0.89, 1.12)</paragraph>
</td>
<td align="center" stylecode="Toprule ">
<paragraph>0.93<br/>(0.85, 1.01)</paragraph>
</td>
<td align="center" stylecode="Toprule ">
<paragraph>0.74<br/>(0.65, 0.86)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>boceprevir</paragraph>
</td>
<td align="center">
<paragraph>800 mg TID,<br/>d 1−6, 25−31</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir<br/>100 mg QD, d 10−31</paragraph>
</td>
<td align="center">
<paragraph>atazanavir: 0.75<br/>(0.64-0.88)</paragraph>
</td>
<td align="center">
<paragraph>atazanavir: 0.65<br/>(0.55-0.78)</paragraph>
</td>
<td align="center">
<paragraph>atazanavir: 0.51<br/>(0.44-0.61)</paragraph>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td align="center">
<paragraph>ritonavir: 0.73<br/>(0.64-0.83)</paragraph>
</td>
<td align="center">
<paragraph>ritonavir: 0.64<br/>(0.58-0.72)</paragraph>
</td>
<td align="center">
<paragraph>ritonavir: 0.55<br/>(0.45-0.67)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>clarithromycin</paragraph>
</td>
<td align="center">
<paragraph>500 mg BID, d 7−10 (n=29) and d 18−21</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 1−10<br/>(n=29)</paragraph>
</td>
<td align="center">
<paragraph>1.06<br/>(0.93, 1.20)</paragraph>
</td>
<td align="center">
<paragraph>1.28<br/>(1.16, 1.43)</paragraph>
</td>
<td align="center">
<paragraph>1.91<br/>(1.66, 2.21)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>didanosine (ddI) (buffered tablets) plus stavudine (d4T)<sup>b</sup>
</paragraph>
</td>
<td align="center">
<paragraph>ddI: 200 mg × 1 dose,<br/>d4T: 40 mg × 1 dose (n=31)</paragraph>
</td>
<td align="center">
<paragraph>400 mg × 1 dose simultaneously with ddI and d4T (n=31)</paragraph>
</td>
<td align="center">
<paragraph>0.11<br/>(0.06, 0.18)</paragraph>
</td>
<td align="center">
<paragraph>0.13<br/>(0.08, 0.21)</paragraph>
</td>
<td align="center">
<paragraph>0.16<br/>(0.10, 0.27)</paragraph>
</td>
</tr>
<tr>
<td></td>
<td align="center">
<paragraph>ddI: 200 mg × 1 dose,<br/>d4T: 40 mg × 1 dose (n=32)</paragraph>
</td>
<td align="center">
<paragraph>400 mg × 1 dose 1 h after ddI + d4T (n=32)</paragraph>
</td>
<td align="center">
<paragraph>1.12<br/>(0.67, 1.18)</paragraph>
</td>
<td align="center">
<paragraph>1.03<br/>(0.64, 1.67)</paragraph>
</td>
<td align="center">
<paragraph>1.03<br/>(0.61, 1.73)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>ddI (enteric-coated [EC] capsules)<sup>c</sup>
</paragraph>
</td>
<td align="center">
<paragraph>400 mg d 8 (fed) (n=34) 400 mg d 19 (fed) (n=31)</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 2−8 (n=34) 300 mg/ritonavir 100 mg QD, d 9−19 (n=31)</paragraph>
</td>
<td align="center">
<paragraph>1.03<br/>(0.93, 1.14)<br/>1.04<br/>(1.01, 1.07)</paragraph>
</td>
<td align="center">
<paragraph>0.99<br/>(0.91, 1.08)<br/>1.00<br/>(0.96, 1.03)</paragraph>
</td>
<td align="center">
<paragraph>0.98<br/>(0.89, 1.08)<br/>0.87<br/>(0.82, 0.92)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>diltiazem</paragraph>
</td>
<td align="center">
<paragraph>180 mg QD, d 7−11 (n=30) and d 19−23</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 1−11<br/>(n=30)</paragraph>
</td>
<td align="center">
<paragraph>1.04<br/>(0.96, 1.11)</paragraph>
</td>
<td align="center">
<paragraph>1.00<br/>(0.95, 1.05)</paragraph>
</td>
<td align="center">
<paragraph>0.98<br/>(0.90, 1.07)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>efavirenz</paragraph>
</td>
<td align="center">
<paragraph>600 mg QD, d 7−20 (n=27)</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 1−20<br/>(n=27)</paragraph>
</td>
<td align="center">
<paragraph>0.41<br/>(0.33, 0.51)</paragraph>
</td>
<td align="center">
<paragraph>0.26<br/>(0.22, 0.32)</paragraph>
</td>
<td align="center">
<paragraph>0.07<br/>(0.05, 0.10)</paragraph>
</td>
</tr>
<tr>
<td></td>
<td align="center">
<paragraph>600 mg QD, d 7−20 (n=13)</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 1−6 (n=23) then 300 mg/ritonavir 100 mg QD, 2 h before efavirenz, d 7−20 (n=13)</paragraph>
</td>
<td align="center">
<paragraph>1.14<br/>(0.83, 1.58)</paragraph>
</td>
<td align="center">
<paragraph>1.39<br/>(1.02, 1.88)</paragraph>
</td>
<td align="center">
<paragraph>1.48<br/>(1.24, 1.76)</paragraph>
</td>
</tr>
<tr>
<td></td>
<td align="center">
<paragraph>600 mg QD, d 11–24 (pm) (n=14)</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir 100 mg QD, d 1–10 (pm) (n=22), then 400 mg QD/ritonavir 100 mg QD, d 11–24 (pm), (simultaneously with efavirenz) (n=14)</paragraph>
</td>
<td align="center">
<paragraph>1.17<br/>(1.08, 1.27)</paragraph>
</td>
<td align="center">
<paragraph>1.00<br/>(0.91, 1.10)</paragraph>
</td>
<td align="center">
<paragraph>0.58<br/>(0.49, 0.69)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>famotidine</paragraph>
</td>
<td align="center">
<paragraph>40 mg BID, d 7−12 (n=15)</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 1−6 (n=45), d 7−12 (simultaneous administration) (n=15)</paragraph>
</td>
<td align="center">
<paragraph>0.53<br/>(0.34, 0.82)</paragraph>
</td>
<td align="center">
<paragraph>0.59<br/>(0.40, 0.87)</paragraph>
</td>
<td align="center">
<paragraph>0.58<br/>(0.37, 0.89)</paragraph>
</td>
</tr>
<tr>
<td></td>
<td align="center">
<paragraph>40 mg BID, d 7−12 (n=14)</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD (pm), d 1−6 (n=14), d 7−12 (10 h after, 2 h before famotidine) (n=14)</paragraph>
</td>
<td align="center">
<paragraph>1.08<br/>(0.82, 1.41)</paragraph>
</td>
<td align="center">
<paragraph>0.95<br/>(0.74, 1.21)</paragraph>
</td>
<td align="center">
<paragraph>0.79<br/>(0.60, 1.04)</paragraph>
</td>
</tr>
<tr>
<td></td>
<td align="center">
<paragraph>40 mg BID, d 11−20 (n=14)<sup>d</sup>
</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir 100 mg QD, d 1−10 (n=46), d 11−20<sup>d</sup> (simultaneous administration) (n=14)</paragraph>
</td>
<td align="center">
<paragraph>0.86<br/>(0.79, 0.94)</paragraph>
</td>
<td align="center">
<paragraph>0.82<br/>(0.75, 0.89)</paragraph>
</td>
<td align="center">
<paragraph>0.72<br/>(0.64, 0.81)</paragraph>
</td>
</tr>
<tr>
<td></td>
<td align="center">
<paragraph>20 mg BID, d 11−17 (n=18)</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir 100 mg QD/tenofovir 300 mg QD, d 1−10 (am) (n=39), d 11−17 (am) (simultaneous administration with am famotidine) (n=18)<sup>e,f</sup>
</paragraph>
</td>
<td align="center">
<paragraph>0.91<br/>(0.84, 0.99)</paragraph>
</td>
<td align="center">
<paragraph>0.90<br/>(0.82, 0.98)</paragraph>
</td>
<td align="center">
<paragraph>0.81<br/>(0.69, 0.94)</paragraph>
</td>
</tr>
<tr>
<td></td>
<td align="center">
<paragraph>40 mg QD (pm),<br/>d 18−24 (n=20)</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir 100 mg QD/tenofovir 300 mg QD, d 1−10 (am) (n=39), d 18−24 (am) (12 h after pm famotidine) (n=20)<sup>f</sup>
</paragraph>
</td>
<td align="center">
<paragraph>0.89<br/>(0.81, 0.97)</paragraph>
</td>
<td align="center">
<paragraph>0.88<br/>(0.80, 0.96)</paragraph>
</td>
<td align="center">
<paragraph>0.77<br/>(0.63, 0.93)</paragraph>
</td>
</tr>
<tr>
<td></td>
<td align="center">
<paragraph>40 mg BID, d 18−24 (n=18)</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir 100 mg QD/tenofovir 300 mg QD, d 1−10 (am) (n=39), d 18−24 (am) (10 h after pm famotidine and 2 h before am famotidine) (n=18)<sup>f</sup>
</paragraph>
</td>
<td align="center">
<paragraph>0.74<br/>(0.66, 0.84)</paragraph>
</td>
<td align="center">
<paragraph>0.79<br/>(0.70, 0.88)</paragraph>
</td>
<td align="center">
<paragraph>0.72<br/>(0.63, 0.83)</paragraph>
</td>
</tr>
<tr>
<td></td>
<td align="center">
<paragraph>40 mg BID, d 11−20 (n=15)</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir 100 mg QD, d 1−10 (am) (n=46), then 400 mg QD/ritonavir 100 mg QD, d 11−20 (am) (n=15)</paragraph>
</td>
<td align="center">
<paragraph>1.02<br/>(0.87, 1.18)</paragraph>
</td>
<td align="center">
<paragraph>1.03<br/>(0.86, 1.22)</paragraph>
</td>
<td align="center">
<paragraph>0.86<br/>(0.68, 1.08)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>fluconazole</paragraph>
</td>
<td align="center">
<paragraph>200 mg QD, d 11−20 (n=29)</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir 100 mg QD, d 1−10 (n=19), d 11−20 (n=29)</paragraph>
</td>
<td align="center">
<paragraph>1.03<br/>(0.95, 1.11)</paragraph>
</td>
<td align="center">
<paragraph>1.04<br/>(0.95, 1.13)</paragraph>
</td>
<td align="center">
<paragraph>0.98<br/>(0.85, 1.13)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>ketoconazole</paragraph>
</td>
<td align="center">
<paragraph>200 mg QD, d 7−13 (n=14)</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 1−13<br/>(n=14)</paragraph>
</td>
<td align="center">
<paragraph>0.99<br/>(0.77, 1.28)</paragraph>
</td>
<td align="center">
<paragraph>1.10<br/>(0.89, 1.37)</paragraph>
</td>
<td align="center">
<paragraph>1.03<br/>(0.53, 2.01)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>nevirapine<sup>g,h</sup>
</paragraph>
</td>
<td align="center">
<paragraph>200 mg BID, d 1–23 (n=23)</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir 100 mg QD, d 4–13, then 400 mg QD/ritonavir 100 mg QD, d 14–23 (n=23)<sup>i</sup>
</paragraph>
</td>
<td align="center">
<paragraph>0.72<br/>(0.60, 0.86)<br/>1.02<br/>(0.85, 1.24)</paragraph>
</td>
<td align="center">
<paragraph>0.58<br/>(0.48, 0.71)<br/>0.81<br/>(0.65, 1.02)</paragraph>
</td>
<td align="center">
<paragraph>0.28<br/>(0.20, 0.40)<br/>0.41<br/>(0.27, 0.60)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>omeprazole</paragraph>
</td>
<td align="center">
<paragraph>40 mg QD, d 7−12 (n=16)<sup>j</sup>
</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 1−6 (n=48), d 7−12 (n=16)</paragraph>
</td>
<td align="center">
<paragraph>0.04<br/>(0.04, 0.05)</paragraph>
</td>
<td align="center">
<paragraph>0.06<br/>(0.05, 0.07)</paragraph>
</td>
<td align="center">
<paragraph>0.05<br/>(0.03, 0.07)</paragraph>
</td>
</tr>
<tr>
<td></td>
<td align="center">
<paragraph>40 mg QD, d 11−20 (n=15)<sup>j</sup>
</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir 100 mg QD, d 1−20 (n=15)</paragraph>
</td>
<td align="center">
<paragraph>0.28<br/>(0.24, 0.32)</paragraph>
</td>
<td align="center">
<paragraph>0.24<br/>(0.21, 0.27)</paragraph>
</td>
<td align="center">
<paragraph>0.22<br/>(0.19, 0.26)</paragraph>
</td>
</tr>
<tr>
<td></td>
<td align="center">
<paragraph>20 mg QD, d 17−23 (am) (n=13)</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir 100 mg QD, d 7−16 (pm) (n=27), d 17−23 (pm) (n=13)<sup>k,l</sup>
</paragraph>
</td>
<td align="center">
<paragraph>0.61<br/>(0.46, 0.81)</paragraph>
</td>
<td align="center">
<paragraph>0.58<br/>(0.44, 0.75)</paragraph>
</td>
<td align="center">
<paragraph>0.54<br/>(0.41, 0.71)</paragraph>
</td>
</tr>
<tr>
<td></td>
<td align="center">
<paragraph>20 mg QD, d 17−23 (am) (n=14)</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir 100 mg QD, d 7−16 (am) (n=27), then 400 mg QD/ritonavir 100 mg QD, d 17−23 (am) (n=14)<sup>m,n</sup>
</paragraph>
</td>
<td align="center">
<paragraph>0.69<br/>(0.58, 0.83)</paragraph>
</td>
<td align="center">
<paragraph>0.70<br/>(0.57, 0.86)</paragraph>
</td>
<td align="center">
<paragraph>0.69<br/>(0.54, 0.88)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>pitavastatin</paragraph>
</td>
<td align="center">
<paragraph>4 mg QD<br/>for 5 days</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD<br/>for 5 days</paragraph>
</td>
<td align="center">
<paragraph>1.13<br/>(0.96, 1.32)</paragraph>
</td>
<td align="center">
<paragraph>1.06<br/>(0.90, 1.26)</paragraph>
</td>
<td align="center">
<paragraph>NA</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>rifabutin</paragraph>
</td>
<td align="center">
<paragraph>150 mg QD, d 15−28 (n=7)</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 1−28<br/>(n=7)</paragraph>
</td>
<td align="center">
<paragraph>1.34<br/>(1.14, 1.59)</paragraph>
</td>
<td align="center">
<paragraph>1.15<br/>(0.98, 1.34)</paragraph>
</td>
<td align="center">
<paragraph>1.13<br/>(0.68, 1.87)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>rifampin</paragraph>
</td>
<td align="center">
<paragraph>600 mg QD, d 17−26 (n=16)</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir 100 mg QD, d 7−16 (n=48), d 17−26 (n=16)</paragraph>
</td>
<td align="center">
<paragraph>0.47<br/>(0.41, 0.53)</paragraph>
</td>
<td align="center">
<paragraph>0.28<br/>(0.25, 0.32)</paragraph>
</td>
<td align="center">
<paragraph>0.02<br/>(0.02, 0.03)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>ritonavir<sup>o</sup>
</paragraph>
</td>
<td align="center">
<paragraph>100 mg QD, d 11−20 (n=28)</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD, d 1−20<br/>(n=28)</paragraph>
</td>
<td align="center">
<paragraph>1.86<br/>(1.69, 2.05)</paragraph>
</td>
<td align="center">
<paragraph>3.38<br/>(3.13, 3.63)</paragraph>
</td>
<td align="center">
<paragraph>11.89<br/>(10.23, 13.82)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>telaprevir</paragraph>
</td>
<td align="center">
<paragraph>750 mg q8h<br/>for 10 days<br/>(n=7)</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir<br/>100 mg QD for 20 days<br/>(n=7)</paragraph>
</td>
<td align="center">
<paragraph>0.85<br/>(0.73, 0.98)</paragraph>
</td>
<td align="center">
<paragraph>1.17<br/>(0.97, 1.43)</paragraph>
</td>
<td align="center">
<paragraph>1.85<br/>(1.40, 2.44)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>tenofovir<sup>p</sup>
</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD, d 9−16 (n=34)</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 2−16<br/>(n=34)</paragraph>
</td>
<td align="center">
<paragraph>0.79<br/>(0.73, 0.86)</paragraph>
</td>
<td align="center">
<paragraph>0.75<br/>(0.70, 0.81)</paragraph>
</td>
<td align="center">
<paragraph>0.60<br/>(0.52, 0.68)</paragraph>
</td>
</tr>
<tr>
<td></td>
<td align="center">
<paragraph>300 mg QD, d 15−42 (n=10)</paragraph>
</td>
<td align="center">
<paragraph>300 mg/ritonavir 100 mg QD, d 1−42 (n=10)</paragraph>
</td>
<td align="center">
<paragraph>0.72<sup>q</sup>
<br/>(0.50, 1.05)</paragraph>
</td>
<td align="center">
<paragraph>0.75<sup>q </sup>
<br/>(0.58, 0.97)</paragraph>
</td>
<td align="center">
<paragraph>0.77<sup>q</sup>
<br/>(0.54, 1.10)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>voriconazole<br/>(Subjects with at least one functional CYP2C19 allele)</paragraph>
</td>
<td align="center">
<paragraph>200 mg BID, d 2−3, 22−30;<br/>400 mg BID, d 1, 21<br/>(n=20)</paragraph>
</td>
<td align="center">
<paragraph>300 mg/ritonavir 100 mg QD, d 11−30<br/>(n=20)</paragraph>
</td>
<td align="center">
<paragraph>0.87<br/>(0.80, 0.96)</paragraph>
</td>
<td align="center">
<paragraph>0.88<br/>(0.82, 0.95)</paragraph>
</td>
<td align="center">
<paragraph>0.80<br/>(0.72, 0.90)</paragraph>
</td>
</tr>
<tr>
<td stylecode="Botrule ">
<paragraph>voriconazole<br/>(Subjects without a functional CYP2C19 allele)</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>50 mg BID, d 2−3, 22−30;<br/>100 mg BID, d 1, 21<br/>(n=8)</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>300 mg/ritonavir 100 mg QD, d 11−30<br/>(n=8)</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>0.81<br/>(0.66, 1.00)</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>0.80<br/>(0.65, 0.97)</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>0.69<br/>(0.54, 0.87)</paragraph>
</td>
</tr>
</tbody>
</table>